Jolieke Schuurmans
About Jolieke Schuurmans
Jolieke Schuurmans is a Pharmaceutical Development Manager at Dechra Pharmaceuticals PLC, where she has worked since 2019. She has extensive experience in the pharmaceutical industry, having held various roles at Alcami Corporation and completed her education in Applied Science.
Current Role at Dechra Pharmaceuticals
Jolieke Schuurmans serves as the Pharmaceutical Development Manager at Dechra Pharmaceuticals PLC. She has held this position since 2019, contributing to the company's operations in Bladel, Provincie Noord-Brabant, Nederland. In her role, she is responsible for overseeing pharmaceutical development processes, ensuring compliance with industry standards, and managing projects related to drug formulation and development.
Previous Experience at Alcami Corporation
Prior to her current role, Jolieke Schuurmans worked at Alcami Corporation in various capacities. She began as a Trainee in 2007 and progressed to roles such as Analytical Chemist, Team Leader Quality Control, and Analytical Chemist - Mass Spectrometry. Her tenure at Alcami lasted from 2008 to 2018, during which she gained extensive experience in analytical chemistry and quality control.
Educational Background
Jolieke Schuurmans completed her education at Fontys University of Applied Sciences, where she earned a Bachelor of Science degree in Applied Science from 2004 to 2008. Prior to that, she attended Varendonck College, achieving HAVO from 1999 to 2004. Her educational background provided her with a strong foundation in scientific principles and practices relevant to her career in pharmaceuticals.
Trainee Experience
In addition to her roles at Alcami Corporation, Jolieke Schuurmans gained valuable experience as a Trainee at the University of Lleida and Fontys Hogescholen in 2006. These positions allowed her to develop practical skills in research and applied sciences, contributing to her professional growth in the pharmaceutical field.
Sabbatical Break
Jolieke Schuurmans took a Sabbatical Break from 2018 to 2019, during which she engaged in extended leave from her professional responsibilities. This period allowed her to reflect on her career and explore new opportunities before resuming her role in pharmaceutical development.